Exor


Exor H1 2025: Strategy still in waiting

26/09/25 -"Exor posts a modest NAV uptick, yet the lift owes more to share buybacks than portfolio strength. Liquidity is at record levels, but the path ahead is ambiguous. Luxury, tech, and healthcare are ..."

Pages
62
Language
English
Published on
26/09/25
You may also be interested by these reports :
26/09/25
Exor posts a modest NAV uptick, yet the lift owes more to share buybacks than portfolio strength. Liquidity is at record levels, but the path ahead ...

23/09/25
The Canal+ (BUY ; France) group was thrown into the LSE water following Vivendi’s (BUY ; France) split into four entities last December. That IPO had ...

22/09/25
The story is old, but the ambition is new. A 300-year-old family holdco now wants to dress up as a modern alternative asset manager. Eurazeo (BUY ; ...

17/09/25
Bolloré published mixed H1 25 results following the deconsolidation of Vivendi. The group continued to buy back its shares at a good pace, thus ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO